Multiponent adult stem cells and methods for isolation

• US 7,015,037 B1
• Filed: 08/21/2002
• Issued: 03/21/2006
• Est. Priority Date: 08/05/1999
• Status: Active Grant

• Current Assignee: ABT Holding Company (Athersys, Inc.), Regents of the University Minnesota
• Original Assignee: MCL Incorporated, Regents of The University of Minnesota (University of Minnesota)
• Inventors: Verfaillie, Catherine M., Furcht, Leo T., Reyes, Morayma
• Primary Examiner(s): Lankford, Jr., Leon B.
• Application Number:
  US10/048,757
• Time in Patent Office: 1,308 Days
• Field of Search: 435/372, 435/366, 435/325
• US Class Current: 435/372
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 2039/5156 expressing foreign proteins
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 39/461 characterised by the cell type used
• CPC Class Codes: A61K 39/46432 Nervous system antigens
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C12N 2501/105 Insulin-like growth factors [IGF]
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 2501/235 Leukemia inhibitory factor [LIF]
• CPC Class Codes: C12N 2503/00 Use of cells in diagnostics
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 5/0607 Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12Y 207/07049 RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Abstract

The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.

Claims

1. An isolated cell population derived from human bone marrow, wherein the cells of the cell population co-express CD49c and CD90, and wherein the cell population has a doubling rate of about 36 hours.

2. An isolated cell population derived from human bone marrow, wherein the cells of the cell population co-express CD49c and CD90, and wherein the cell population has a doubling rate of 36 hours.

3. An isolated cell population derived from human bone marrow, wherein the cells of the cell population co-express CD49c and CD90, and wherein the cell population has a doubling rate of about 36–

48 hours.

4. An isolated cell population derived from human bone marrow, wherein the cells of the cell population co-express CD49c and CD90, and wherein the cells of the population can differentiate into cell types of at least two of ectodermal, endodermal, or mesodermal lineages.

5. An isolated cell population derived from human bone marrow, wherein the cells of the cell population co-express CD49c, CD90, and telomerase.